**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Chanhold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg
Chanhold 30 mg spot-on solution for dogs 2.6-5.0 kg
Chanhold 45 mg spot-on solution for cats 2.6–7.5 kg
Chanhold 60 mg spot-on solution for cats 7.6–10.0 kg
Chanhold 60 mg spot-on solution for dogs 5.1–10.0 kg
Chanhold 120 mg spot-on solution for dogs 10.1–20.0 kg
Chanhold 240 mg spot-on solution for dogs 20.1–40.0 kg
Chanhold 360 mg spot-on solution for dogs 40.1–60.0 kg

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each pipette contains:

**Active substances:**

| | | | |
|---|---|---|---|
| Chanhold 15 mg for cats and dogs | 6% w/v solution | Selamectin | 15 mg |
| Chanhold 30 mg for dogs | 12% w/v solution | Selamectin | 30 mg |
| Chanhold 45 mg for cats | 6% w/v solution | Selamectin | 45 mg |
| Chanhold 60 mg for cats | 6% w/v solution | Selamectin | 60 mg |
| Chanhold 60 mg for dogs | 12% w/v solution | Selamectin | 60 mg |
| Chanhold 120 mg for dogs | 12% w/v solution | Selamectin | 120 mg |
| Chanhold 240 mg for dogs | 12% w/v solution | Selamectin | 240 mg |
| Chanhold 360 mg for dogs | 12% w/v solution | Selamectin | 360 mg |

**Excipients:**

| **Qualitative composition of excipients and other constituents** | **Quantitative composition if that information is essential for proper administration of the veterinary medicinal product** |
|---|---|
| Butylated hydroxytoluene (E321) | 0.8 mg/ml |
| Dipropylene glycol methyl ether | |
| Isopropyl alcohol | |

Clear colourless to yellow solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Dogs and cats.

### 3.2 Indications for use for each target species

Cats and dogs:

- **Treatment and prevention of flea infestations** caused by *Ctenocephalides* spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The veterinary medicinal product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter

up to seven weeks of age. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.

- **Prevention of heartworm disease** caused by *Dirofilaria immitis* with monthly administration.
  The veterinary medicinal product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning treatmentwith the veterinary medicinal product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the veterinary medicinal product has been administered monthly. This veterinary medicinal product is not effective against adult *D. immitis.*

- **Treatment of ear mites** (*Otodectes cynotis*).

Cats:

- Treatment of biting lice infestations *(Felicola subrostratus*)
- Treatment of adult roundworms (*Toxocara cati*)
- Treatment of adult intestinal hookworms (*Ancylostoma tubaeforme).*

Dogs:

- Treatment of biting lice infestations (*Trichodectes canis*)
- Treatment of sarcoptic mange (caused by *Sarcoptes scabiei*)
- Treatment of adult intestinal roundworms (*Toxocara canis*).

### 3.3 Contraindications

Do not use in animals under 6 weeks of age.
Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

### 3.4 Special warnings

Animals may be bathed 2 hours after treatment without loss of efficacy.
Do not apply when the animal's hair coat is wet. However, shampooing or soaking the animal 2 or more hours after treatment will not reduce the efficacy of the product.
For ear mite treatment, do not apply directly to the ear canal.
It is important to apply the dose as indicated to minimize the quantity that the animal can lick off. If significant licking does occur, a brief period of hypersalivation may rarely be observed in cats.

### 3.5 Special precautions for use

Special precautions for safe use in the target species:

This veterinary medicinal product is to be applied to the skin surface only. Do not administer orally or parenterally.

Keep treated animals away from fires and other sources of ignition for at least 30 minutes or until the hair coat is dry.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product is highly flammable; keep away from heat, sparks, open flames or other sources of ignition.

The veterinary medicinal product is a skin and eye irritant.

Do not smoke, eat or drink while handling the veterinary medicinal product.

Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and seek medical advice immediately and show the package leaflet or the label to the physician.

Avoid direct contact with treated animals until the application site is dry. On the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children. Used applicators should be disposed of immediately and not left within the sight or reach of children.

People with sensitive skin or known allergy to veterinary medicinal products of this type should handle the product with caution.

Special precautions for the protection of the environment:

Do not allow treated animals to bathe in water courses until at least two hours after treatment administration.

Other precautions:

Not Applicable

### 3.6 Adverse events

Cats:

| | |
|---|---|
| Rare<br>(1 to 10 animals / 10 000 animals treated): | application site alopecia[1,2]<br>application site hair change[3]<br>hypersalivation[6] |
| Very rare<br>(<1 animal / 10 000 animals treated, including isolated reports): | application site irritation[1,4]<br>neurological signs (including seizures)[5] |

Dogs:

| | |
|---|---|
| Rare<br>(1 to 10 animals / 10 000 animals treated): | application site hair change[3] |
| Very rare<br>(<1 animal / 10 000 animals treated, including isolated reports): | neurological signs (including seizures)[5] |

[1] Normally self-resolving, but symptomatic therapy may be applicable in some circumstances.
[2] Mild and transient.
[3] Local temporary clumping of the hair at the application site and/or an occasional appearance of a small quantity of a white powder which typically disappear within 24 hours of treatment administration and does not affect either the safety or efficacy of the veterinary medicinal product.
[4] Transient and focal.
[5] Reversible as with other macrocyclic lactones.

[6]Briefly if there is significant licking.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:
The veterinary medicinal product can be used during pregnancy and lactation of cats and dogs.

Fertility:
The veterinary medicinal product can be used in breeding cats and dogs.

### 3.8 Interaction with other medicinal products and other forms of interaction

None known.

### 3.9 Administration routes and dosage

The veterinary medicinal product should be administered as a single application of a single dose delivering a minimum of 6 mg/kg selamectin.

When concurrent infestations or infections in the same animal are to be treated with the veterinary medicinal product, only one application of the recommended 6 mg/kg dose should be administered at any one time. The appropriate length of the treatment period for individual parasites is specified below.

Administer in accordance with the following table:

| Cats (kg) | Product | mg of selamectin dispensed | Potency (mg/ml) | Nominal pipette size (ml) |
|---|---|---|---|---|
| ≤ 2.5 | 1 pipette of Chanhold 15 mg for cats and dogs ≤ 2.5 kg | 15 | 60 | 0.25 |
| 2.6–7.5 | 1 pipette of Chanhold 45 mg for cats 2.6-7.5 kg | 45 | 60 | 0.75 |
| 7.6–10.0 | 1 pipette of Chanhold 60 mg for cats 7.6-10 kg | 60 | 60 | 1.0 |
| > 10 | | Appropriate combination of pipettes | 60 | Appropriate combination of pipettes |

| Dogs (kg) | Product | mg of selamectin dispensed | Potency (mg/ml) | Nominal pipette size (ml) |
|---|---|---|---|---|
| ≤ 2.5 | 1 pipette of Chanhold 15 mg for cats and dogs ≤ 2.5 kg | 15 | 60 | 0.25 |
| 2.6–5.0 | 1 pipette of Chanhold 30 mg for dogs 2.6-5.0 kg | 30 | 120 | 0.25 |

| | | | | |
|---|---|---|---|---|
| 5.1–10.0 | 1 pipette of Chanhold 60 mg for dogs 5.1-10.0 kg | 60 | 120 | 0.5 |
| 10.1–20.0 | 1 pipette of Chanhold 120 mg for dogs 10.1-20.0 kg | 120 | 120 | 1.0 |
| 20.1–40.0 | 1 pipette of Chanhold 240 mg for dogs 20.1-40.0 kg | 240 | 120 | 2.0 |
| 40.1–60.0 | 1 pipette of Chanhold 360 mg for dogs 40.1-60.0 kg | 360 | 120 | 3.0 |
| > 60 | | Appropriate combination of pipettes | 60/120 | Appropriate combination of pipettes |

Flea treatment and prevention (cats and dogs)

Following administration of the veterinary medicinal product, the adult fleas on the animal are killed, no viable eggs are produced, and larvae (found only in the environment) are also killed. This stops flea reproduction, breaks the flea lifecycle and may aid in the control of existing environmental flea infestations in areas to which the animal has access.

For the prevention of flea infestations, the veterinary medicinal product should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestations in the litter up to seven weeks of age.

For use as part of a treatment strategy for flea allergy dermatitis the veterinary medicinal product should be administered at monthly intervals.

Prevention of heartworm disease (cats and dogs)

The veterinary medicinal product may be administered year-round or at least within one month of the animal's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of the veterinary medicinal product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms. When replacing another heartworm preventive veterinary medicinal product in a heartworm disease prevention programme, the first dose of the veterinary medicinal product must be given within a month of the last dose of the former medication.

Treatment of roundworm infections (cats and dogs)

A single dose of the veterinary medicinal product should be administered.

Treatment of biting lice (cats and dogs)

A single dose of the veterinary medicinal product should be administered.

Treatment of ear mites (cats)

A single dose of the veterinary medicinal product should be administered.

Treatment of ear mites (dogs)

A single dose of the veterinary medicinal product should be administered. Loose debris should be gently removed from the external ear canal at the time of treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

Treatment of hookworm infections (cats)

A single dose of the veterinary medicinal product should be administered.

Treatment of sarcoptic mange (dogs)

For complete elimination of the mites, a single dose of the veterinary medicinal product should be administered for two consecutive months.

Method of administration:

Remove the product pipette from its protective package.
Hold the pipette upright.
Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette.
Snap back the tip.
Part the animal's coat at the base of the neck in front of the shoulder blades until the skin is visible.
Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot.

Apply to the skin at the base of the neck in front of the shoulder blades.

Avoid contact between the product and your fingers.




### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No undesirable effects were observed after the administration of 10 times the recommended dose.

Selamectin was administered at 3 times the recommended dose to cats and dogs infected with adult heartworms and no undesirable effects were observed. Selamectin was also administered at 3 times the recommended dose to breeding male and female cats and dogs, including pregnant and lactating females nursing their litters and at 5 times the recommended dose to ivermectin-sensitive Collies, and no undesirable effects were observed.

### 3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

### 3.12 Withdrawal periods

Not applicable.

## 4. PHARMACOLOGICAL INFORMATION

### 4.1 ATCvet code: QP54AA05

### 4.2 Pharmacodynamics

Selamectin is a semi-synthetic compound of the avermectin class. Selamectin paralyses and/or kills a wide range of invertebrate parasites through interference with their chloride channel conductance causing disruption of normal neurotransmission. This inhibits the electrical activity of nerve cells in nematodes and muscle cells in arthropods leading to their paralysis and/or death.

Selamectin has adulticidal, ovicidal and larvicidal activity against fleas. Therefore, it effectively breaks the flea life cycle by killing adults (on the animal), preventing the hatching of eggs (on the animal and in its environment) and by killing larvae (environment only). Debris from selamectin-treated pets kills flea eggs and larvae not previously exposed to selamectin and thus may aid in the control of existing environmental flea infestations in areas to which the animal has access.

Activity has also been demonstrated against heartworm larvae.

### 4.3 Pharmacokinetics

Following spot on administration selamectin is absorbed from the skin reaching maximum plasma concentrations approximately 1 and 3 days after administration in cats and dogs respectively.

Following absorption from the skin selamectin distributes systemically and is slowly eliminated from plasma as manifested in detectable plasma concentrations in dogs and cats 30 days after administration of a single topical dose at 6 mg/kg. The prolonged persistence and slow elimination of selamectin from plasma is reflected in the terminal elimination half-life values of 8 and 11 days in cats and dogs respectively. The systemic persistence of selamectin in plasma and the lack of extensive metabolism provide effective concentrations of selamectin for the duration of the inter-dosing interval (30 days).

## 5. PHARMACEUTICAL PARTICULARS

### 5.1 Major incompatibilities

Not applicable.

### 5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

### 5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage conditions.

### 5.4 Nature and composition of immediate packaging

The veterinary medicinal product is presented in a white plastic pipette formed from a layer of polypropylene/cyclic olefin copolymer/polypropylene with a layer of polyethylene/ethylene vinyl alcohol/polyethylene.

The veterinary medicinal product is available in packs of three pipettes (all strengths), six pipettes (all strengths except 15 mg), or fifteen pipettes (15 mg strength only) in individual foil sachets within an outer carton.

Not all pack sizes may be marketed.

### 5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as selamectin may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## 6. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.

## 7. MARKETING AUTHORISATION NUMBER(S)

EU/2/19/236/001-016

## 8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 17/04/2019

## 9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD/MM/YYYY}

## 10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (*https://medicines.health.europa.eu/veterinary*).

**ANNEX II**

**OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None.

**ANNEX III**

**LABELLING AND PACKAGE LEAFLET**

# A. LABELLING

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARTON, 15 mg**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Chanhold 15 mg spot-on solution

## 2. STATEMENT OF ACTIVE SUBSTANCES

Each pipette contains:

Selamectin 15 mg

## 3. PACKAGE SIZE

3 pipettes
15 pipettes

0.25 ml

## 4. TARGET SPECIES

Cats and dogs weighing 2.5 kg or less

## 5. INDICATIONS

## 6. ROUTES OF ADMINISTRATION

Spot-on use.

## 7. WITHDRAWAL PERIODS

## 8. EXPIRY DATE

Exp. {mm/yyyy}

## 9. SPECIAL STORAGE PRECAUTIONS

## 10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

## 11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

## 12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

## 13. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

## 14. MARKETING AUTHORISATION NUMBERS

EU/2/19/236/001 3 pipettes
EU/2/19/236/002 15 pipettes

## 15. BATCH NUMBER

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARTON, 30 mg, 60 mg, 120 mg, 240 mg, 360 mg for dogs**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Chanhold 30 mg spot-on solution
Chanhold 60 mg spot-on solution
Chanhold 120 mg spot-on solution
Chanhold 240 mg spot-on solution
Chanhold 360 mg spot-on solution

## 2. STATEMENT OF ACTIVE SUBSTANCES

Each pipette contains:

Selamectin 30 mg
Selamectin 60 mg
Selamectin 120 mg
Selamectin 240 mg
Selamectin 360 mg

## 3. PACKAGE SIZE

3 pipettes
6 pipettes

0.25 ml
0.5 ml
1.0 ml
2.0 ml
3.0 ml

## 4. TARGET SPECIES

Dogs weighing 2.6–5.0 kg.
Dogs weighing 5.1–10.0 kg.
Dogs weighing 10.1–20.0 kg.
Dogs weighing 20.1–40.0 kg.
Dogs weighing 40.1–60.0 kg.

## 5. INDICATIONS

## 6. ROUTES OF ADMINISTRATION

Spot-on use.

## 7. WITHDRAWAL PERIODS

## 8. EXPIRY DATE

Exp. {mm/yyyy}

## 9. SPECIAL STORAGE PRECAUTIONS

## 10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

## 11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

## 12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

## 13. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

## 14. MARKETING AUTHORISATION NUMBERS

EU/2/19/236/007 - 3 pipettes
EU/2/19/236/008 - 6 pipettes
EU/2/19/236/009 - 3 pipettes
EU/2/19/236/010 - 6 pipettes
EU/2/19/236/011 - 3 pipettes
EU/2/19/236/012 - 6 pipettes EU/2/19/236/013 - 3 pipettes
EU/2/19/236/014 - 6 pipettes
EU/2/19/236/015 - 3 pipettes
EU/2/19/236/016 - 6 pipettes

## 15. BATCH NUMBER

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**CARTON, 45 mg, 60 mg for cats**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Chanhold 45 mg spot-on solution
Chanhold 60 mg spot-on solution

## 2. STATEMENT OF ACTIVE SUBSTANCES

Each pipette contains:

Selamectin 45 mg
Selamectin 60 mg

## 3. PACKAGE SIZE

3 pipettes
6 pipettes

0.75 ml
1.0 ml

## 4. TARGET SPECIES

Cats weighing 2.6–7.5 kg.
Cats weighing 7.6–10.0 kg.

## 5. INDICATIONS

## 6. ROUTES OF ADMINISTRATION

Spot-on use.

## 7. WITHDRAWAL PERIODS

## 8. EXPIRY DATE

Exp. {mm/yyyy}

## 9. SPECIAL STORAGE PRECAUTIONS

## 10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

## 11. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

## 12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

## 13. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

## 14. MARKETING AUTHORISATION NUMBERS

EU/2/19/236/003 - 3 pipettes
EU/2/19/236/004 - 6 pipettes
EU/2/19/236/005 - 3 pipettes
EU/2/19/236/006 - 6 pipettes

## 15. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**SACHET FOIL, 15 mg, 30 mg, 45 mg, 60 mg, 120 mg, 240 mg, 360 mg**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Chanhold 15 mg spot-on solution for cats and dogs
Chanhold 30 mg spot-on solution for dogs
Chanhold 45 mg spot-on solution for cats
Chanhold 60 mg spot-on solution for cats
Chanhold 60 mg spot-on solution for dogs
Chanhold 120 mg spot-on solution for dogs
Chanhold 240 mg spot-on solution for dogs
Chanhold 360 mg spot-on solution for dogs

## 2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

15 mg selamectin
30 mg selamectin
45 mg selamectin
60 mg selamectin
120 mg selamectin
240 mg selamectin
360 mg selamectin

## 3. BATCH NUMBER

Lot {number}

## 4. EXPIRY DATE

Exp. {mm/yyyy}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**PIPETTE, 15 mg, 30 mg, 45 mg, 60 mg, 120 mg, 240 mg, 360 mg**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Chanhold



## 2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCE(S)

0.25 ml
0.5 ml
0.75 ml
1.0 ml
2.0 ml
3.0 ml

## 3. BATCH NUMBER

Lot {number}

## 4. EXPIRY DATE

Exp. {mm/yyyy}

# B. PACKAGE LEAFLET

# PACKAGE LEAFLET

## 1. Name of the veterinary medicinal product

Chanhold 15 mg spot-on solution for cats and dogs ≤ 2.5 kg
Chanhold 30 mg spot-on solution for dogs 2.6–5.0 kg
Chanhold 45 mg spot-on solution for cats 2.6–7.5 kg
Chanhold 60 mg spot-on solution for cats 7.6–10.0 kg
Chanhold 60 mg spot-on solution for dogs 5.1–10.0 kg
Chanhold 120 mg spot-on solution for dogs 10.1–20.0 kg
Chanhold 240 mg spot-on solution for dogs 20.1–40.0 kg
Chanhold 360 mg spot-on solution for dogs 40.1–60.0 kg

## 2. Composition

**Active substances:**

| | | | |
|---|---|---|---|
| Chanhold 15 mg for cats and dogs | 6% w/v solution | Selamectin | 15 mg |
| Chanhold 30 mg for dogs | 12% w/v solution | Selamectin | 30 mg |
| Chanhold 45 mg for cats | 6% w/v solution | Selamectin | 45 mg |
| Chanhold 60 mg for cats | 6% w/v solution | Selamectin | 60 mg |
| Chanhold 60 mg for dogs | 12% w/v solution | Selamectin | 60 mg |
| Chanhold 120 mg for dogs | 12% w/v solution | Selamectin | 120 mg |
| Chanhold 240 mg for dogs | 12% w/v solution | Selamectin | 240 mg |
| Chanhold 360 mg for dogs | 12% w/v solution | Selamectin | 360 mg |

**Excipients:**

| **Qualitative composition of excipients and other constituents** | **Quantitative composition if that information is essential for proper administration of the veterinary medicinal product** |
|---|---|
| Butylated hydroxytoluene (E321) | 0.8 mg/ml |

Clear colourless to yellow solution.

## 3. Target species

Cats and dogs



## 4. Indications for use

Cats and dogs:

- **Treatment and prevention of flea infestations** caused by *Ctenocephalides* spp. for one month following a single administration. This is as a result of the adulticidal, larvicidal and ovicidal properties of the product. The product is ovicidal for 3 weeks after administration. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will also aid in the prevention of flea infestations in the litter up to seven weeks of

age. The product can be used as part of a treatment strategy for flea allergy dermatitis and through its ovicidal and larvicidal action may aid in the control of existing environmental flea infestations in areas to which the animal has access.

- **Prevention of heartworm disease** caused by *Dirofilaria immitis* with monthly administration.
  The product may be safely administered to animals infected with adult heartworms, however, it is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more living in countries where a vector exists should be tested for existing adult heartworm infections before beginning treatment with the product. It is also recommended that dogs should be tested periodically for adult heartworm infections, as an integral part of a heartworm prevention strategy, even when the product has been administered monthly. This product is not effective against adult *D. immitis.*

- **Treatment of ear mites** (*Otodectes cynotis*).

Cats:
- Treatment of biting lice infestations *(Felicola subrostratus*)
- Treatment of adult roundworms (*Toxocara cati*)
- Treatment of adult intestinal hookworms (*Ancylostoma tubaeforme).*

Dogs:
- Treatment of biting lice infestations (*Trichodectes canis*)
- Treatment of sarcoptic mange (caused by *Sarcoptes scabiei*)
- Treatment of adult intestinal roundworms (*Toxocara canis*).

## 5. Contraindications

Do not use in animals under 6 weeks of age.
Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

## 6. Special warnings

Special warnings:

Animals may be bathed 2 hours after treatment without loss of efficacy.
Do not apply when the animal's hair coat is wet. However, shampooing or soaking the animal 2 or more hours after treatment will not reduce the efficacy of the product.
For ear mite treatment, do not apply directly to the ear canal.
It is important to apply the dose as indicated to minimize the quantity that the animal can lick off. If significant licking does occur, a brief period of hypersalivation may rarely be observed in cats.

Special precautions for safe use in the target species:

This veterinary medicinal product is to be applied to the skin surface only. Do not administer orally or parenterally.

Keep treated animals away from fires and other sources of ignition for at least 30 minutes or until the hair coat is dry.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This product is highly flammable; keep away from heat, sparks, open flames or other sources of ignition.

The product is a skin and eye irritant.
Do not smoke, eat or drink while handling the product.
Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and seek medical advice immediately and show the package leaflet or the label to the physician.

Avoid direct contact with treated animals until the application site is dry. On the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children. Used applicators should be disposed of immediately and not left within the sight or reach of children.

People with sensitive skin or known allergy to veterinary medicinal products of this type should handle the product with caution.

Special precautions for the protection of the environment:

Do not allow treated animals to bathe in water courses until at least two hours after treatment administration.

Pregnancy and lactation:

Can be used in pregnant and lactating cats and dogs.

Fertility:

Can be used in breeding cats and dogs

Interaction with other medicinal products and other forms of interaction:

None known.

Overdose:

No undesirable effects were observed after the administration of 10 times the recommended dose. Selamectin was administered at 3 times the recommended dose to cats and dogs infected with adult heartworms and no undesirable effects were observed. Selamectin was also administered at 3 times the recommended dose to breeding male and female cats and dogs, including pregnant and lactating females nursing their litters and at 5 times the recommended dose to ivermectin-sensitive Collies, and no undesirable effects were observed.

## 7. Adverse events

Cats:

| | |
|---|---|
| Rare<br>(1 to 10 animals / 10 000 animals treated): | application site alopecia[1,2]<br>application site hair change[3]<br>hypersalivation[6] |
| Very rare<br>(<1 animal / 10 000 animals treated, including isolated reports): | application site irritation[1,4]<br>neurological signs (including seizures)[5] |

Dogs:

| | |
|---|---|
| Rare<br>(1 to 10 animals / 10 000 animals treated): | application site hair change[3] |
| Very rare<br>(<1 animal / 10 000 animals treated, including isolated reports): | neurological signs (including seizures)[5] |

[1] Normally self-resolving, but symptomatic therapy may be applicable in some circumstances.
[2] Mild and transient.
[3] Local temporary clumping of the hair at the application site and/or an occasional appearance of a small quantity of a white powder which typically disappear within 24 hours of treatment administration and does not affect either the safety or efficacy of the veterinary medicinal product.
[4] Transient and focal.
[5] Reversible as with other macrocyclic lactones.
[6] Briefly if there is significant licking.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or its local representative using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

## 8. Dosage for each species, routes and method of administration

Spot-on use.

The product should be administered as a single application of a single dose delivering a minimum of 6 mg/kg selamectin. When concurrent infestations or infections in the same animal are to be treated with the veterinary medicinal product, only one application of the recommended 6 mg/kg dose should be administered at any one time. The appropriate length of the treatment period for individual parasites is specified below.

Administer in accordance with the following table:

| **Cats (kg)** | **Product** | **mg of selamectin dispensed** | **Potency (mg/ml)** | **nominal pipette size, ml** |
|---|---|---|---|---|
| ≤ 2.5 | 1 pipette of Chanhold 15 mg for cats and dogs ≤ 2.5 kg | 15 | 60 | 0.25 |
| 2.6–7.5 | 1 pipette of Chanhold 45 mg for cats 2.6-7.5 kg | 45 | 60 | 0.75 |
| 7.6–10.0 | 1 pipette of Chanhold 60 mg for cats 7.6-10 kg | 60 | 60 | 1.0 |
| > 10 | | Appropriate combination of pipettes | 60 | Appropriate combination of pipettes |

| Dogs (kg) | Product | mg of selamectin dispensed | Potency (mg/ml) | nominal pipette size, ml |
|---|---|---|---|---|
| ≤ 2.5 | 1 pipette of Chanhold 15 mg for cats and dogs ≤ 2.5 kg | 15 | 60 | 0.25 |
| 2.6–5.0 | 1 pipette of Chanhold 30 mg for dogs 2.6-5.0 kg | 30 | 120 | 0.25 |
| 5.1–10.0 | 1 pipette of Chanhold 60 mg for dogs 5.1-10.0 kg | 60 | 120 | 0.5 |
| 10.1–20.0 | 1 pipette of Chanhold 120 mg for dogs 10.1-20.0 kg | 120 | 120 | 1.0 |
| 20.1–40.0 | 1 pipette of Chanhold 240 mg for dogs 20.1-40.0 kg | 240 | 120 | 2.0 |
| 40.1–60.0 | 1 pipette of Chanhold 360 mg for dogs 40.1-60.0 kg | 360 | 120 | 3.0 |
| > 60 | | Appropriate combination of pipettes | 60/120 | Appropriate combination of pipettes |

Flea treatment and prevention (cats and dogs)

Following administration of the veterinary medicinal product, the adult fleas on the animal are killed, no viable eggs are produced, and larvae (found only in the environment) are also killed. This stops flea reproduction, breaks the flea lifecycle and may aid in the control of existing environmental flea infestations in areas to which the animal has access.

For the prevention of flea infestations, the veterinary medicinal product should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. Through a reduction in the flea population, monthly treatment of pregnant and lactating animals will aid prevention of flea infestations in the litter up to seven weeks of age.

For use as part of a treatment strategy for flea allergy dermatitis the veterinary medicinal product should be administered at monthly intervals.

Prevention of heartworm disease (cats and dogs)

The veterinary medicinal product may be administered year-round or at least within one month of the animal's first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of the veterinary medicinal product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms. When replacing another heartworm preventive veterinary medicinal product in a heartworm disease prevention programme, the first dose of the veterinary medicinal product must be given within a month of the last dose of the former medication.

Treatment of roundworm infections (cats and dogs)

A single dose of the veterinary medicinal product should be administered.

Treatment of biting lice (cats and dogs)

A single dose of the veterinary medicinal product should be administered.

Treatment of ear mites (cats)

A single dose of the veterinary medicinal product should be administered.

Treatment of ear mites (dogs)

A single dose of the veterinary medicinal product should be administered. Loose debris should be gently removed from the external ear canal at the time of treatment. A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment.

Treatment of hookworm infections (cats)

A single dose of the veterinary medicinal product should be administered.

Treatment of sarcoptic mange (dogs)

For complete elimination of the mites, a single dose of the veterinary medicinal product should be administered for two consecutive months.

## 9. Advice on correct administration

Method of administration:
Remove the product pipette from its protective package.
Hold the pipette upright.
Tap the narrow part of the pipette to ensure the contents remain within the main body of the pipette.
Snap back the tip.
Part the animal's coat at the base of the neck in front of the shoulder blades until the skin is visible.
Place the tip of the pipette on the skin and squeeze the pipette several times to empty its contents completely and directly onto the skin in one spot.

Apply to the skin at the base of the neck in front of the shoulder blades.

Avoid contact between the product and your fingers.




## 10. Withdrawal periods

Not applicable.

## 11. Special storage precautions

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use this veterinary medicinal product after the expiry date which is stated on the label, carton, after Exp. The expiry date refers to the last day of that month.

## 12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

The product should not enter water courses as Selamectin may be dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon pharmacist how to dispose of medicines no longer required.

## 13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

## 14. Marketing authorisation numbers and pack sizes

EU/2/19/236/001-016

The veterinary medicinal product is available in packs of three pipettes (all strengths), six pipettes (all strengths except 15 mg), or fifteen pipettes (15 mg strength only).

Not all pack sizes may be marketed.

## 15. Date on which the package leaflet was last revised

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (*https://medicines.health.europa.eu/veterinary*).

## 16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:

Chanelle Pharmaceuticals Manufacturing Ltd,
Loughrea,
Co. Galway,
Ireland
Tel: + 353 91 841788
vetpharmacoviggroup@chanellegroup.ie

Local representatives and contact details to report suspected adverse events:

**België/Belgique/Belgien**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irland/ Irlande/ Ierland
Tél/Tel: +353 91 841788

**Република България**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Ирландия
Tél/Tel: +353 91 841788

**Česká republika**
Místní zástupce držitele rozhodnutí o registraci:
Orion Pharma s.r.o.
Na Strži 2102/61a
CZ-140 00 Praha
Tel: +420 227 027 263

**Danmark**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irland
Tel: + 353 91 841788

**Deutschland**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irland
Tel: + 353 91 841788

**Eesti**
**Müügiloa hoidja kohalik esindaja:**
AS Dimedium
Roheline 9, Tahtvere,
61410 Tartu, Estonia
Tel: +372 739 0660

**Ελλάδα**
Τοπικός αντιπρόσωπος του κατόχου της άδειας κυκλοφορίας:
Neocell Ε.Π.Ε.
10ο χλμ. Εθνικής Οδού Αθηνών- Λαμίας
14452 Μεταμόρφωση, Αθήνα,
Tel: 210 2844333

**España**
Fatro Ibérica S.L.
Constitución 1, P.B. 3
08960 Sant Just Desvern
(Barcelona) España

**Luxembourg/Luxemburg**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irland
Tél/Tel: +353 91 841788

**Magyarország**
Magyarországi képviselet:
Orion Pharma Kft.
Pap Károly u. 4-6
HU-1139 Budapest
Tel.: +36 1 2370603

**Malta**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
L-irlanda
Tel: + 353 91 841788

**Nederland**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Ierland
Tel: + 353 91 841788

**Norge**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irland
Tel: + 353 91 841788

**Österreich**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irland
Tel: + 353 91 841788

**Polska**
Lokalny przedstawiciel podmiotu odpowiedzialnego
Orion Pharma Poland Sp. z o.o.
ul. Fabryczna 5A
PL-00-446 Warszawa
Tel: +48 22 833 31 77

**Portugal**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irlanda

Tel. + 34 93 480 2277

**France**
Laboratoire Perrigo France
200 Avenue De Paris
92320 Chatillon
France
Tél: +33 (0)1 55 48 18 00
CHCIFRLOPFQualiteProduit@perrigo.com

**Ireland**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Ireland
Tel: + 353 91 841788

**Ísland**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Írland
Sími: + 353 91 841788

**Italia**
Azienda Terapeutica Italiana A.T.I**.** s.r.l.
Via Emilia, 285
Ozzano dell'Emilia (BO),
Italia
Tel: +39 051791501

**Κύπρος**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Ιρλανδία
Τηλ: + 353 91 841788

**Latvija**
AS Dimedium Latvija
Ozolu iela 28, Jaunmarupe,
Marupes novads, LV-2166, Latvia
Tel: +371 67610001

**Lietuva**
Dimedium Lietuva UAB
Islandijos pl. 217-13, LT-49165
Kaunas, Lithuania
Tel: +370 615 64241

Tel: + 353 91 841788

**România**
S.C. MONTERO VET S.R.L.,
Oras Bragadiru
Strada Celofibrei nr. 25-27
077025, România
Tel: 0729 290 738
client@montero.vet

**Slovenija**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irska
Tel: + 353 91 841788

**Slovenská republika**
Miestny zástupca držiteľa rozhodnutia o registrácii:
Orion Pharma s.r.o.
Na strži 2102/61a
140 00 Praha
Česko
Tel: +420 227 027 263

**Suomi/Finland**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irlanti
Puh/Tel: + 353 91 841788

**Sverige**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Irland
Tel: + 353 91 841788

**United Kingdom (Northern Ireland)**
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea
Co. Galway
Ireland
Tel: + 353 91 841788

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.